NCT03695757: Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgG

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 19 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Only healthy volunteers are eligible for Part A; Advanced solid tumor patients are eligible for Part B
Exclusions: Patients with known symptomatic active brain metastases that require treatment- see trial for details

Comments are closed.

Up ↑